These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30134297)

  • 21. First reported use of elvitegravir and cobicistat during pregnancy.
    Schalkwijk S; Colbers A; Konopnicki D; Greupink R; Russel FG; Burger D;
    AIDS; 2016 Mar; 30(5):807-8. PubMed ID: 26913711
    [No Abstract]   [Full Text] [Related]  

  • 22. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.
    Schalkwijk S; Colbers A; Konopnicki D; Gingelmaier A; Lambert J; van der Ende M; Moltó J; Burger D;
    Clin Infect Dis; 2017 Oct; 65(8):1335-1341. PubMed ID: 28595298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.
    Schalkwijk S; Colbers A; Konopnicki D; Weizsäcker K; Moltó J; Tenorio CH; Hawkins D; Taylor G; Wood C; van der Ende M; Burger D;
    AIDS; 2016 May; 30(8):1239-44. PubMed ID: 26836789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model.
    Faure-Bardon V; Mandelbrot L; Duro D; Dussaux C; Le M; Peytavin G
    AIDS; 2018 Jan; 32(3):321-325. PubMed ID: 29112064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
    Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
    Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
    Nguyen T; McNicholl I; Custodio JM; Szwarcberg J; Piontkowsky D
    AIDS Rev; 2016; 18(2):101-11. PubMed ID: 27196356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pregnancy on emtricitabine pharmacokinetics.
    Stek AM; Best BM; Luo W; Capparelli E; Burchett S; Hu C; Li H; Read JS; Jennings A; Barr E; Smith E; Rossi SS; Mirochnick M
    HIV Med; 2012 Apr; 13(4):226-35. PubMed ID: 22129166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
    Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
    Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
    HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
    Salama E; Hill L; Patel N; Best BM; Momper JD
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
    Perry CM
    Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
    Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
    AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
    Colbers A; Best B; Schalkwijk S; Wang J; Stek A; Hidalgo Tenorio C; Hawkins D; Taylor G; Kreitchmann R; Burchett S; Haberl A; Kabeya K; van Kasteren M; Smith E; Capparelli E; Burger D; Mirochnick M;
    Clin Infect Dis; 2015 Nov; 61(10):1582-9. PubMed ID: 26202768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
    Else LJ; Douglas M; Dickinson L; Back DJ; Khoo SH; Taylor GP
    Antimicrob Agents Chemother; 2012 Feb; 56(2):816-24. PubMed ID: 22106215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.